Study Title
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
Protocol ID
ANBL2131
Condition/s
Ganglioneuroblastoma, Nodular
Neuroblastoma
Neuroblastoma
Diagnosis Stage
Newly Diagnosed
Location
NSW, QLD, VIC, WA, NZ
Sponsor
Children's Oncology Group
Links
Trial Status
Open
Sites
Perth Children's Hospital
Starship Hospital
Sydney Children's Hospital
Queensland Children's Hospital
Royal Children's Hospital
Starship Hospital
Sydney Children's Hospital
Queensland Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 30 Years
International registry ID's
NCT06172296
| Study Title | A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma |
|---|---|
| Protocol ID | ANBL2131 |
| Disease (Sub Disease) | Ganglioneuroblastoma, Nodular Neuroblastoma |
| Diagnosis Stage | Newly Diagnosed |
| Location | NSW / QLD / VIC / WA / NZ |
| Sponsor | Children's Oncology Group/ |
| Links | https://clinicaltrials.gov/study/NCT06172296 |
| Trial Status | Open |
| Trial Open Date | 14/10/2024 |
| Sites | Perth Children's Hospital / Starship Hospital / Sydney Children's Hospital / Queensland Children's Hospital/ Royal Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | up to 30 Years |
| International registry ID's | NCT06172296 |